TITLE

The FDA: Doctors, Investigators, and Translational Research

AUTHOR(S)
Eaglstein, William H
PUB. DATE
November 2015
SOURCE
Journal of Investigative Dermatology;Nov2015, Vol. 135 Issue 11, p2555
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The author reflects on the role of the medical scientists and physicians in helping the society to be aware and conversant on the policies imposed by the U.S. Food and Drug Administration (FDA). He cites the impact of the FDA's policies on the developmental course of any preventive, diagnostic and therapeutic agents in the country. The author also argues that the publication of his book "The FDA for Doctors" will not be of interests to physicians.
ACCESSION #
110833770

 

Related Articles

  • What Every Physician Should Know About Generic Drugs. Mohler, Phil; Nolan, Steve // Family Practice Management;Mar2002, Vol. 9 Issue 3, p45 

    Focuses on the knowledge of physicians about generic drugs in the U.S. Attitudes of physicians, pharmacists, and consumers towards generic medication; Grant of the U.S. Food and Drug Administration for generic-drug manufacturers; Bioequivalence of generic drugs to brand-name twins. INSETS:...

  • Survey finds many physicians not aware of drug's approval status.  // PharmacoEconomics & Outcomes News;10/3/2009, Issue 588, p6 

    The article discusses a survey which revealed that several physicians in the U.S. do not have enough knowledge of the indications of commonly used prescription drugs approved by the Food and Drug Administration (FDA). This survey was participated by 600 psychiatrists and 599 primary care...

  • Rotavirus vaccine and intussusception.  // WHO Drug Information;2007, Vol. 21 Issue 1, p8 

    The article reports on the notification of the U.S. Food and Drug Administration (FDA) to the health care providers concerning complication of intussusception after the administration of rotavirus live oral pentavalent vaccine for the prevention of rotavirus gastroenteritis. Intussusception is a...

  • New flu fighters. Verkler, Erin // Prevention;Jan2004, Vol. 56 Issue 1, p29 

    Focuses on the introduction of flu vaccines in the U.S. Peak seasons of flu; Symptoms of flu; Information on the nasal-spray flu vaccine approved by the U.S. Food and Drug Administration; Details on a super-vaccine being developed by researchers.

  • Accelerated dosing schedule for hepatitis vaccine receives FDA approval.  // Pharmacy Today;May2007, Vol. 13 Issue 5, p2 

    The article reports on the approval of accelerated dosing schedule for hepatitis vaccine by the U.S. Food and Drug Administration (FDA). The accelerated dosing schedule will benefit the emergency first-care responders and patients that are planning to travel in an area with high risk on...

  • FDA OKs first NSAID/PPI combo pack.  // Drug Topics;12/8/2003, Vol. 147 Issue 23, p9 

    Reports on the U.S. Food and Drug Administration's approval of lanzoprazole delayed-release capsules/naproxen tablets for reducing the risk of nonsteroidal anti-inflammatory drug-associated gastric ulcers. Manufacturer of the drug; Availability of the drug.

  • FDA Issues Public Health Advisory on Blue Dye.  // ASHA Leader;11/4/2003, Vol. 8 Issue 20, p2 

    Focuses on the advisory given by the U.S. Food and Drug Administration concerning the usage blue dye. Overview on what is blue dye all about; Unfavorable results that users experienced; Recommendations of health professionals for those using blue dye.

  • FDA approves vaccine to prevent rota virus gastroenteritis in infants.  // Healthcare Purchasing News;Mar2006, Vol. 30 Issue 3, p58 

    The article reports on the approval of the rotavirus vaccine RotaTeq by the U.S. Food and Drug Administration. The diseases associated with the rotavirus are listed. The percentage of rotavirus gastroenteritis prevented by the vaccine is given.

  • FDA Licensure of Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), and Poliovirus Vaccine Combined, (PEDIARIXâ„¢) for Use in Infants.  // MMWR: Morbidity & Mortality Weekly Report;3/14/2003, Vol. 52 Issue 10, p203 

    Reports on the licensing of a combined vaccine by the U.S. Food and Drug Administration for use in infants ages 2, 4 and 6 months. Groups that recommended the combined vaccine; Advantage of combination vaccines; Content of the vaccine.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics